SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose Reduced Passive Stake in AIM ImmunoTech Inc. to 4.99%

Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, disclosing a 4.99% passive ownership stake in AIM ImmunoTech Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in AIM ImmunoTech Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 3,349,740 shares of AIM ImmunoTech Inc. Common Stock.
• This represents 4.99% of the total outstanding shares of the class, indicating their stake is now below the 5% threshold.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of passive ownership and does not contain information that would significantly alter the company's operational or financial outlook. The slight reduction in stake to just under 5% is a neutral event in itself.

Positives

• The continued disclosure by Armistice Capital, LLC and Steven Boyd, even with a stake just under 5%, provides transparency regarding significant institutional interest in AIM ImmunoTech Inc.

Future Outlook

The document does not contain any forward-looking statements or guidance from AIM ImmunoTech Inc. or the Reporting Persons regarding the company's future performance.

Management Comments

• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure required when an institutional investor's passive ownership in a public company changes or falls below a certain threshold. It indicates a significant, non-controlling investment in a company operating in the biotechnology sector, as implied by 'ImmunoTech'.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's updated position in the company.

Key Dates

Keywords

AIM ImmunoTech, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment